EPS Revision Screener Winners: ATEC Jumps 19.9%, HUBS, TMDX Lead Gains
Alphatec Holdings (ATEC) surged 19.9% to $10.77 after our EPS revision screener detected an 86.6% next-year growth estimate on September 9. HubSpot (HUBS) gained 11.2% to $248.61 on a 26.1% estimate, while TransMedics (TMDX) rose 10.0% to $90.42 after reiterating 2026 guidance alongside a new CFO appointment. Navan (NAVN) and Fossil (FOSL) also delivered strong gains of 9.8% and 9.3%, respectively.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| ATEC | Healthcare | 2026-09-09 | N/A | +19.9% |
| HUBS | Technology | 2026-09-10 | N/A | +11.2% |
| TMDX | Healthcare | 2026-09-11 | N/A | +10.0% |
| NAVN | Technology | 2026-09-10 | N/A | +9.8% |
| FOSL | Consumer Cyclical | 2026-09-10 | +664.7pp | +9.3% |
Why did ATEC stock jump in September 2026?
ATEC jumped 19.9% (from $8.98 to $10.77) after the EPS revision screener flagged an 86.6% next-year growth estimate on September 9, 2026.
The medical device company, which specializes in spine surgery technologies, caught the screener's attention as analysts raised forward earnings expectations. With no company-specific news in the window, the rally reflects growing confidence in the healthcare sector's earnings recovery and ATEC's improving margin profile. The sharp price move on above-average volume suggests institutional accumulation following the estimate revision.
ATEC EPS revision history → · Screener snapshot from 2026-09-09 →
FAQ: ATEC
Why did ATEC stock jump in September 2026?
ATEC jumped 19.9% from $8.98 to $10.77 after the EPS revision screener detected an 86.6% next-year EPS growth estimate on September 9, 2026.
What is ATEC's EPS growth estimate?
ATEC's next-year EPS growth estimate is 86.6%, as flagged by the EPS revision screener on September 9, 2026.
Is ATEC a buy after the rally?
The 86.6% next-year EPS growth estimate suggests strong earnings momentum, but with no company-specific news, investors should monitor upcoming quarterly reports for confirmation.
Why did HUBS stock jump in September 2026?
HUBS jumped 11.2% (from $223.55 to $248.61) after the EPS revision screener identified a 26.1% next-year growth estimate on September 10, 2026.
The CRM platform provider benefited from a broader technology sector rebound as investors rotated back into high-growth software names. HubSpot's consistent revenue growth and expanding customer base have made it a favorite among analysts despite a challenging macro environment for SaaS valuations. The revision likely reflects expectations for improved operating leverage as the company scales its AI-powered marketing tools.
HUBS EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: HUBS
Why did HUBS stock jump in September 2026?
HUBS jumped 11.2% from $223.55 to $248.61 after the EPS revision screener flagged a 26.1% next-year EPS growth estimate on September 10, 2026.
What is HUBS's EPS growth estimate?
HubSpot's next-year EPS growth estimate is 26.1%, according to the EPS revision screener data from September 10, 2026.
Is HUBS a buy after the rally?
The 11.2% rally reflects renewed confidence in HubSpot's earnings trajectory, but the 26.1% growth estimate is moderate compared to peers, suggesting valuation discipline is warranted.
Why did TMDX stock jump in September 2026?
TMDX jumped 10.0% (from $82.18 to $90.42) after the EPS revision screener detected a 55.0% next-year growth estimate on September 11, 2026, reinforced by a CFO appointment and guidance reiteration.
On September 10, TransMedics named Fernando Araujo as CFO and reiterated its full-year 2026 revenue guidance, signaling operational continuity and financial discipline. The portable organ perfusion specialist continues to benefit from strong adoption of its OCS technology across transplant centers. The combination of analyst estimate revisions and management's confident outlook drove the stock's sharp post-detection gain.
TMDX EPS revision history → · Screener snapshot from 2026-09-11 →
FAQ: TMDX
Why did TMDX stock jump in September 2026?
TMDX jumped 10.0% from $82.18 to $90.42 after the EPS revision screener flagged a 55.0% next-year growth estimate on September 11, 2026, reinforced by a CFO appointment and reiterated guidance.
What caused TMDX's surge?
TMDX surged after naming a new CFO and reiterating 2026 revenue guidance on September 10, combined with an EPS revision screener detection of 55.0% next-year growth.
What is TMDX's EPS growth estimate?
TransMedics' next-year EPS growth estimate is 55.0%, as identified by the EPS revision screener on September 11, 2026.
Why did FOSL stock jump in September 2026?
FOSL jumped 9.3% (from $4.49 to $4.91) after the EPS revision screener detected a massive upward revision in next-year growth estimate from 111.5% to 776.2% on September 10, 2026.
The consumer cyclical company, known for watches and accessories, saw its earnings outlook dramatically improve, though no specific news was identified in the window. The 664.7 percentage point revision suggests analysts are anticipating a significant turnaround in profitability, possibly driven by cost-cutting initiatives or a rebound in discretionary spending. The low-priced stock's sharp move reflects speculative interest in deep-value names with explosive earnings potential.
FOSL EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: FOSL
Why did FOSL stock jump in September 2026?
FOSL jumped 9.3% from $4.49 to $4.91 after the EPS revision screener detected a massive upward revision in next-year growth estimate from 111.5% to 776.2% on September 10, 2026.
What is FOSL's EPS growth estimate?
Fossil Group's next-year EPS growth estimate was revised to 776.2% on September 10, 2026, up from 111.5%, representing a 664.7 percentage point increase.
Is FOSL a buy after the rally?
The extreme EPS revision to 776.2% suggests a potential earnings turnaround, but with no company-specific news, the rally appears speculative—investors should await confirmation from upcoming financial reports.
Today's top performers highlight the market's willingness to reward stocks with strong EPS revision signals, particularly in healthcare and technology. The outsized gains in ATEC, HUBS, and TMDX suggest that earnings estimate revisions remain a powerful catalyst for price appreciation, even without accompanying news.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →